Citation: | Jiali Li, Ting Chen, Xixi Xiang, Peiyan Kong, Jun Rao, Xiaoqi Wang, Lei Gao, Cheng Zhang, Xi Zhang, Li Gao. Long-term efficacy of haploidentical hematopoietic stem cell transplantation in the treatment of pediatric acute leukemia[J]. Blood&Genomics. doi: 10.46701/BG.2023022022039 |
[1] |
Elgarten CW, Aplenc R. Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy[J]. Curr Opin Pediatr, 2020, 32(1): 57−66. doi: 10.1097/MOP.0000000000000855
|
[2] |
O'Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(7): 926−957. doi: 10.6004/jnccn.2017.0116
|
[3] |
Brown P, Inaba H, Annesley C, et al. Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(1): 81−112. doi: 10.6004/jnccn.2020.0001
|
[4] |
Chen Y, Cheng Y, Suo P, et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation[J]. Br J Haematol, 2017, 179(4): 598−605. doi: 10.1111/bjh.14923
|
[5] |
Liu J, Zhang X, Zhong JF, et al. CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia[J]. Immunotherapy, 2017, 9(13): 1115−1125. doi: 10.2217/imt-2017-0072
|
[6] |
Wang X, Huang R, Zhang X, et al. Current status and prospects of hematopoietic stem cell transplantation in China[J]. Chin Med J (Engl), 2022, 135(12): 1394−1403. doi: 10.1097/CM9.0000000000002235
|
[7] |
Gao L, Zhang C, Gao L, et al. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China[J]. J Hematol Oncol, 2015, 8: 90. doi: 10.1186/s13045-015-0186-5
|
[8] |
Wang Y, Chen H, Chen J, et al. The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China[J]. Cancer Lett, 2018, 438: 63−75. doi: 10.1016/j.canlet.2018.08.030
|
[9] |
Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. the 2014 diagnosis and staging working group report[J]. Biol Blood Marrow Transplant, 2015, 21(3): 389−401.e1. doi: 10.1016/j.bbmt.2014.12.001
|
[10] |
Ruggeri A, Labopin M, Ciceri F, et al. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission[J]. Bone Marrow Transplant, 2016, 51(4): 610−611. doi: 10.1038/bmt.2015.305
|
[11] |
Zheng FM, Zhang X, Li CF, et al. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: a multi-center study[J]. Cancer Commun (Lond), 2020, 40(2–3): 93−104. doi: 10.1002/cac2.12014
|
[12] |
Jia Y, Li W, Wang L, et al. Allele and haplotype frequencies of human leukocyte antigen-A, -B, -C, -DRB1, and -DQB1 in Chinese patients with hematological diseases[J]. Blood Genom, 2018, 2(1): 27−37. doi: 10.46701/APJBG.2018012017064
|
[13] |
Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell donors for pediatric patients[J]. Bone Marrow Transplant, 2008, 41(2): 207−214. doi: 10.1038/sj.bmt.1705963
|
[14] |
Bolaños-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease[J]. Blood, 2012, 120(22): 4285−4291. doi: 10.1182/blood-2012-07-438408
|
[15] |
Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma[J]. Hum Immunol, 1990, 29(2): 79−91. doi: 10.1016/0198-8859(90)90071-v
|
[16] |
Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings[J]. N Engl J Med, 1985, 313(13): 765−771. doi: 10.1056/NEJM198509263131301
|
[17] |
Bertaina A, Merli P, Rutella S, et al. HLA-haploidentical stem cell transplantation after removal of alphabeta+ T and B cells in children with nonmalignant disorders[J]. Blood, 2014, 124(5): 822−826. doi: 10.1182/blood-2014-03-563817
|
[18] |
Xu LP, Liu KY, Liu DH, et al. The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis[J]. Bone Marrow Transplant, 2010, 45(6): 985−992. doi: 10.1038/bmt.2009.311
|
[19] |
Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation[J]. Biol Blood Marrow Transplant, 2015, 21(11): 1863−1869. doi: 10.1016/j.bbmt.2015.07.032
|
[20] |
Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation[J]. Blood, 2001, 98(12): 3221−3227. doi: 10.1182/blood.v98.12.3221
|
[21] |
Li Y, Chang Y, Xu L, et al. Negative association of donor age with CD34(+) cell dose in mixture allografts of G-CSF-primed bone marrow and G-CSF-mobilized peripheral blood harvests[J]. Chin Med J (Engl), 2014, 127(20): 3597–3601.
|
[22] |
Wang Y, Chang YJ, Xu LP, et al. Who is the best donor for a related HLA haplotype-mismatched transplant?[J]. Blood, 2014, 124(6): 843−850. doi: 10.1182/blood-2014-03-563130
|
[23] |
Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia[J]. Cell, 2012, 150(2): 264−278. doi: 10.1016/j.cell.2012.06.023
|
[24] |
Gooptu M, Antin JH. GVHD prophylaxis 2020[J]. Front Immunol, 2021, 12: 605726. doi: 10.3389/fimmu.2021.605726
|
[25] |
Gao L, Liu J, Zhang Y, et al. Low incidence of acute graft-versus-host disease with short-term tacrolimus in haploidentical hematopoietic stem cell transplantation[J]. Leuk Res, 2017, 57: 27−36. doi: 10.1016/j.leukres.2017.02.006
|
[26] |
Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro[J]. Blood, 2008, 111(7): 3675−3683. doi: 10.1182/blood-2008-01-130146
|
[27] |
Zhou X, Lu X, Tang L, et al. Optimization of ATG dose in haploid hematopoietic stem cell transplantation for hematologic malignancies[J]. Chin J Hematol (in Chinese), 2020, 41(7): 557−563. doi: 10.3760/cma.j.issn.0253-2727.2020.07.005
|
[28] |
Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective[J]. Biol Blood Marrow Transplant, 2009, 15(10): 1143−1238. doi: 10.1016/j.bbmt.2009.06.019
|
[29] |
Bazinet A, Popradi G. A general practitioner's guide to hematopoietic stem-cell transplantation[J]. Curr Oncol, 2019, 26(3): 187−191. doi: 10.3747/co.26.5033
|
[30] |
Mo XD, Tang BL, Zhang XH, et al. Comparison of outcomes after umbilical cord blood and unmanipulated haploidentical hematopoietic stem cell transplantation in children with high-risk acute lymphoblastic leukemia[J]. Int J Cancer, 2016, 139(9): 2106−2115. doi: 10.1002/ijc.30249
|
[31] |
Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial[J]. J Clin Oncol, 2015, 33(11): 1265−1274. doi: 10.1200/JCO.2014.58.9747
|
[32] |
Kawamura K, Nakasone H, Kurosawa S, et al. Refractory graft-versus-host disease-free, relapse-free survival as an accurate and easy-to-calculate endpoint to assess the long-term transplant success[J]. Biol Blood Marrow Transplant, 2018, 24(7): 1521−1526. doi: 10.1016/j.bbmt.2018.02.004
|
[33] |
Sakaguchi H, Watanabe N, Matsumoto K, et al. Comparison of donor sources in hematopoietic stem cell transplantation for childhood acute leukemia: a nationwide retrospective study[J]. Biol Blood Marrow Transplant, 2016, 22(12): 2226−2234. doi: 10.1016/j.bbmt.2016.09.020
|